Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$10.8 million.

  • Pharmaceuticals' Consolidated Net Income fell 2802.46% to -$10.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$29.4 million, marking a year-over-year decrease of 1384.49%. This contributed to the annual value of -$38.1 million for FY2024, which is 4356.45% down from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' Consolidated Net Income is -$10.8 million, which was down 2802.46% from -$10.1 million recorded in Q1 2025.
  • Pharmaceuticals' Consolidated Net Income's 5-year high stood at -$3.3 million during Q4 2023, with a 5-year trough of -$14.9 million in Q4 2022.
  • In the last 4 years, Pharmaceuticals' Consolidated Net Income had a median value of -$7.8 million in 2023 and averaged -$8.1 million.
  • Examining YoY changes over the last 5 years, Pharmaceuticals' Consolidated Net Income showed a top increase of 7782.11% in 2023 and a maximum decrease of 4747.3% in 2023.
  • Quarter analysis of 4 years shows Pharmaceuticals' Consolidated Net Income stood at -$14.9 million in 2022, then surged by 77.82% to -$3.3 million in 2023, then tumbled by 156.48% to -$8.5 million in 2024, then fell by 28.02% to -$10.8 million in 2025.
  • Its Consolidated Net Income stands at -$10.8 million for Q2 2025, versus -$10.1 million for Q1 2025 and -$8.5 million for Q2 2024.